Treatment Adherence in Patients with Type 2 Diabetes Mellitus: Associations with Clinical and Metabolic Factors
Pharmata, cilt.6, sa.2, ss.45-53, 2026 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 6 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.62425/pharmata.1896761
- Dergi Adı: Pharmata
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.45-53
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İnönü Üniversitesi Adresli: Evet
Özet
Objective: This study aimed to assess treatment adherence according to antidiabetic treatment regimens and its associations with medication burden and clinical outcomes in patients with type 2 diabetes mellitus (T2DM).
Methods: This cross-sectional study was conducted between January and April 2024 in the endocrinology department of a tertiary care hospital. Adult patients diagnosed with T2DM for at least one year were included. Sociodemographic data, comorbidities, diabetes-related complications, treatment and lifestyle characteristics, laboratory parameters (HbA1c and C-peptide), and self-reported adherence were recorded. Treatment adherence was assessed using the validated Turkish version of the Treatment Adherence in Type 2 Diabetes Mellitus (TAT2DM) Scale.
Results: The study included 198 patients with T2DM. Hypertension was the most common comorbidity, and diabetic peripheral neuropathy was the most frequent complication. The mean TAT2DM score was 85.2 ± 9.2. HbA1c levels were positively correlated with the total number of medications, oral antidiabetic drugs (OADs), and insulin products (P<.001), while C-peptide levels were negatively correlated with the number of insulin products (P=.010). The total TAT2DM score was negatively associated with the number of insulin products (P=.008) and adherence was significantly higher among patients who exercised regularly (P=.024). Treatment adherence and HbA1c levels differed significantly across antidiabetic regimens, with higher adherence and HbA1c observed in patients receiving combined insulin and OAD therapy (P<.05).
Conclusion: Treatment adherence and glycemic outcomes vary across antidiabetic treatment regimens, supporting the need for personalized diabetes management. Keywords: Diabetes mellitus, hypoglycemic agents, insulin, treatment adherence